首页 > 最新文献

Lancet Healthy Longevity最新文献

英文 中文
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study 台湾 2 型糖尿病患者体弱对 GLP-1 受体激动剂与 SGLT2 抑制剂有效性和安全性的影响:一项全国范围的回顾性纵向研究
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.07.004
Prof Fei-Yuan Hsiao PhD , Elise Chia-Hui Tan PhD , Lin-Chieh Meng MS , Yi-Chin Lin PharmD MS , Ho-Min Chen MS , Shang-Ting Guan PharmD , Prof Der-Cherng Tarng MD PhD , Prof Chih-Yuan Wang MD PhD , Prof Liang-Kung Chen
<div><h3>Background</h3><p>GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by frailty in real-world settings. We aimed to compare the clinical effectiveness and safety of GLP-1 receptor agonists and SGLT2 inhibitors in managing type 2 diabetes, with a specific focus on stratifying people by their frailty status.</p></div><div><h3>Methods</h3><p>In this retrospective, nationwide, longitudinal study, we identified people (aged ≥20 years) with type 2 diabetes who newly initiated either a GLP-1 receptor agonist or an SGLT2 inhibitor during the period Jan 1, 2017 to Dec 31, 2019 from the Taiwan National Health Insurance database. Individuals were excluded if they had been diagnosed with cancer, received dialysis for kidney failure, or had prescriptions for a GLP-1 receptor agonist or an SGLT2 inhibitor, within 1 year before the index date. Mortality data were collected from the Taiwan National Death Registry. Eligible individuals were categorised into three frailty subgroups—fit, mild frailty, and moderate or severe frailty—on the basis of the multimorbidity frailty index. Propensity score matching (1:1) was used to balance covariates between recipients of GLP-1 receptor agonists and SGLT2 inhibitors among each frailty subgroup. Clinical outcomes of interest included three-point major adverse cardiovascular events (non-fatal acute myocardial infarction, non-fatal stroke, and fatal cardiovascular disease), all-cause mortality, hospitalisation for heart failure, dialysis or renal transplant, severe diabetic foot complications, retinopathy, hospitalisation for severe hyperglycaemia, and hospitalisation for severe hypoglycaemia. The association between the use of a GLP-1 receptor agonist versus an SGLT2 inhibitor and the risk of the outcomes of interest among each frailty subgroup was examined using a subdistribution hazard model.</p></div><div><h3>Findings</h3><p>We identified 320 210 people with type 2 diabetes, of whom 280 163 met the eligibility criteria, who initiated either a GLP-1 receptor agonist (n=22 968; mean age 57·7 years [SD 13·9], 11 338 [49·4%] were female, and 11 630 [50·6%] were male) or SGLT2 inhibitor (n=257 195; mean age 58·8 years [12·3], 107 988 [42·0%] were female, and 149 207 [58·0%] were male) during 2017–19. After matching, 11 882, 7210, and 3414 pairs of GLP-1 receptor agonist and SGLT2 inhibitor users were assigned in the fit, mild frailty, and moderate or severe frailty subgroups. All clinical outcomes were comparable between users of GLP-1 receptor agonists and SGLT2 inhibitors among each frailty subgroup, except for a higher risk of hospitalisation for severe hyperglycaemia with GLP-1 receptor agonists than with SGLT2 inhibitors in the mild frailty subgroup (subdistribution hazard ratio 1·25 [95% CI 1·13–1·38]; p<0·0001) and a higher risk of d
背景根据随机临床试验的结果,GLP-1 受体激动剂和 SGLT2 抑制剂正越来越多地用于 2 型糖尿病患者;然而,在现实世界中,临床结果是否会受到体弱的影响却鲜为人知。我们的目的是比较 GLP-1 受体激动剂和 SGLT2 抑制剂在控制 2 型糖尿病方面的临床有效性和安全性,特别关注根据虚弱状况对患者进行分层。方法在这项回顾性、全国范围的纵向研究中,我们从台湾国民健康保险数据库中识别了在 2017 年 1 月 1 日至 2019 年 12 月 31 日期间新开始使用 GLP-1 受体激动剂或 SGLT2 抑制剂的 2 型糖尿病患者(年龄≥20 岁)。如果患者在指标日期前一年内被诊断出患有癌症、因肾衰竭而接受透析治疗,或有GLP-1受体激动剂或SGLT2抑制剂处方,则排除在外。死亡率数据来自台湾国家死亡登记处。根据多病虚弱指数,将符合条件的患者分为三个虚弱亚组--适合、轻度虚弱、中度或重度虚弱。采用倾向得分匹配法(1:1)平衡各虚弱亚组中 GLP-1 受体激动剂和 SGLT2 抑制剂接受者之间的协变量。相关临床结果包括三点主要不良心血管事件(非致死性急性心肌梗死、非致死性中风和致死性心血管疾病)、全因死亡率、心力衰竭住院、透析或肾移植、严重糖尿病足并发症、视网膜病变、严重高血糖住院和严重低血糖住院。使用亚分布危险模型研究了使用 GLP-1 受体激动剂与 SGLT2 抑制剂之间的关系,以及每个虚弱亚组中出现相关结果的风险。研究结果我们确定了320 210名2型糖尿病患者,其中280 163人符合资格标准,他们在2017-19年间开始使用GLP-1受体激动剂(n=22 968;平均年龄57-7岁[SD 13-9],女性11 338人[49-4%],男性11 630人[50-6%])或SGLT2抑制剂(n=257 195;平均年龄58-8岁[12-3],女性107 988人[42-0%],男性149 207人[58-0%])。配对后,11 882、7210 和 3414 对 GLP-1 受体激动剂和 SGLT2 抑制剂使用者被分配到体质良好、轻度虚弱和中度或重度虚弱亚组。在各虚弱亚组中,GLP-1 受体激动剂和 SGLT2 抑制剂使用者的所有临床结果均相当,但在轻度虚弱亚组中,GLP-1 受体激动剂使用者因严重高血糖住院的风险高于 SGLT2 抑制剂使用者(亚组危险比 1-25 [95% CI 1-13-1-38];p<0-0001),在体格健壮(2-43 [1-82-3-23]; p<0-0001)、轻度虚弱(3-93 [3-03-5-09]; p<0-0001)和中度或重度虚弱(2-60 [2-03-3-31]; p<0-0001)亚组中,使用 GLP-1 受体激动剂比使用 SGLT2 抑制剂有更高的透析或肾移植风险。解释根据虚弱状况制定明确、最新的 GLP-1 受体激动剂和 SGLT2 抑制剂使用指南,可改善 2 型糖尿病的管理。
{"title":"Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study","authors":"Prof Fei-Yuan Hsiao PhD ,&nbsp;Elise Chia-Hui Tan PhD ,&nbsp;Lin-Chieh Meng MS ,&nbsp;Yi-Chin Lin PharmD MS ,&nbsp;Ho-Min Chen MS ,&nbsp;Shang-Ting Guan PharmD ,&nbsp;Prof Der-Cherng Tarng MD PhD ,&nbsp;Prof Chih-Yuan Wang MD PhD ,&nbsp;Prof Liang-Kung Chen","doi":"10.1016/j.lanhl.2024.07.004","DOIUrl":"10.1016/j.lanhl.2024.07.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by frailty in real-world settings. We aimed to compare the clinical effectiveness and safety of GLP-1 receptor agonists and SGLT2 inhibitors in managing type 2 diabetes, with a specific focus on stratifying people by their frailty status.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;In this retrospective, nationwide, longitudinal study, we identified people (aged ≥20 years) with type 2 diabetes who newly initiated either a GLP-1 receptor agonist or an SGLT2 inhibitor during the period Jan 1, 2017 to Dec 31, 2019 from the Taiwan National Health Insurance database. Individuals were excluded if they had been diagnosed with cancer, received dialysis for kidney failure, or had prescriptions for a GLP-1 receptor agonist or an SGLT2 inhibitor, within 1 year before the index date. Mortality data were collected from the Taiwan National Death Registry. Eligible individuals were categorised into three frailty subgroups—fit, mild frailty, and moderate or severe frailty—on the basis of the multimorbidity frailty index. Propensity score matching (1:1) was used to balance covariates between recipients of GLP-1 receptor agonists and SGLT2 inhibitors among each frailty subgroup. Clinical outcomes of interest included three-point major adverse cardiovascular events (non-fatal acute myocardial infarction, non-fatal stroke, and fatal cardiovascular disease), all-cause mortality, hospitalisation for heart failure, dialysis or renal transplant, severe diabetic foot complications, retinopathy, hospitalisation for severe hyperglycaemia, and hospitalisation for severe hypoglycaemia. The association between the use of a GLP-1 receptor agonist versus an SGLT2 inhibitor and the risk of the outcomes of interest among each frailty subgroup was examined using a subdistribution hazard model.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;We identified 320 210 people with type 2 diabetes, of whom 280 163 met the eligibility criteria, who initiated either a GLP-1 receptor agonist (n=22 968; mean age 57·7 years [SD 13·9], 11 338 [49·4%] were female, and 11 630 [50·6%] were male) or SGLT2 inhibitor (n=257 195; mean age 58·8 years [12·3], 107 988 [42·0%] were female, and 149 207 [58·0%] were male) during 2017–19. After matching, 11 882, 7210, and 3414 pairs of GLP-1 receptor agonist and SGLT2 inhibitor users were assigned in the fit, mild frailty, and moderate or severe frailty subgroups. All clinical outcomes were comparable between users of GLP-1 receptor agonists and SGLT2 inhibitors among each frailty subgroup, except for a higher risk of hospitalisation for severe hyperglycaemia with GLP-1 receptor agonists than with SGLT2 inhibitors in the mild frailty subgroup (subdistribution hazard ratio 1·25 [95% CI 1·13–1·38]; p&lt;0·0001) and a higher risk of d","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100621"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001375/pdfft?md5=e893d77bc3881c4e4d26dc5179146936&pid=1-s2.0-S2666756824001375-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving health-related quality of life after kidney transplantation using lifestyle interventions 利用生活方式干预改善肾移植后与健康相关的生活质量
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.07.010
Roemer J Janse , Yvette Meuleman
{"title":"Improving health-related quality of life after kidney transplantation using lifestyle interventions","authors":"Roemer J Janse ,&nbsp;Yvette Meuleman","doi":"10.1016/j.lanhl.2024.07.010","DOIUrl":"10.1016/j.lanhl.2024.07.010","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100627"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001430/pdfft?md5=b9ef50fa11daa29e39a67a7641e67bff&pid=1-s2.0-S2666756824001430-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study 老年医学 8 项虚弱与老年癌症患者健康相关生活质量之间的关系(PROGNOSIS-G8):一项丹麦单中心前瞻性队列研究。
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/S2666-7568(24)00118-1
Helena Møgelbjerg Ditzel MD , Ann-Kristine Weber Giger MD PhD , Cecilia Margareta Lund MD PhD , Prof Henrik Jørn Ditzel MD DMSc , Sören Möller PhD , Prof Per Pfeiffer MD PhD , Prof Jesper Ryg MD PhD , Prof Marianne Ewertz MD DMSc , Trine Lembrecht Jørgensen MD PhD
<div><h3>Background</h3><p>Health-related quality of life (HRQoL) is highly valued among older adults with cancer. The Geriatric 8 screening tool identifies individuals with frailty, but its association with HRQoL remains sparsely investigated. Herein, we evaluate whether Geriatric 8 frailty is associated with short-term and long-term HRQoL in older patients with cancer.</p></div><div><h3>Methods</h3><p>In this Danish single-centre, prospective cohort study, patients aged 70 years and older, referred to oncological assessment for solid cancers, were screened with the Geriatric 8. Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Core 30 (QLQ-C30) and Elderly 14 (ELD14) questionnaires at baseline, 3 months, 6 months, 9 months, and 12 months. Patient characteristics were obtained from medical records. Differences in mean global health status and QoL (GHS), measured using the two seven-point Likert scale questions from the EORTC QLQ-C30 regarding overall health and QoL during the past week, between patients with frailty (defined as a Geriatric 8 score of ≤14) and without frailty within 12 months were the primary outcome. Secondary outcomes were differences in the mean EORTC Summary Score comprised of all questions from the QLQ-C30 except for those included in the GHS and a question concerning financial difficulties, and five functional (physical, role, and social functioning, maintaining purpose, and family support from the EORTC QLQ-C30 and the EORTC-QLQ-ELD14), and five symptom scales (fatigue, pain, mobility, future worries, and burden of illness from the EORTC-QLQ-C30 and the EORTC-QLQ-ELD14). Analyses were done using linear mixed models. All primary and secondary outcomes were adjusted for gender, treatment intent, and cancer type and the primary outcome was also assessed by means of a responder analysis.</p></div><div><h3>Findings</h3><p>Between June 1, 2020 and Oct 15, 2021, 1398 eligible patients were screened with the Geriatric 8 (908 [65%] with frailty and 490 [35%] without frailty) and provided medical record data. Of these patients, 707 (51%) also provided HRQoL data (437 [62%] with frailty and 270 [38%] without frailty). When adjusted, patients with frailty had poorer GHS (–15·1, 95% CI –18·5 to –11·6; p<0·0001) at baseline and throughout follow-up (3 months –7·4, –11·0 to –3·7, p=0·0001; 6 months –11·7, –15·5 to –7·9, p<0·0001; 9 months –10·4, –14·3 to –6·5, p<0·0001; 12 months –10·4, –14·6 to –6·2, p<0·0001) compared to patients without frailty. Adjusted summary scores were also poorer for patients with frailty (–9·9, 95% CI –12·1 to –7·6; p<0·0001) compared to patients without frailty at baseline and throughout follow-up (3 months –8·2, –10·5 to –5·8, p=0·0001; 6 months –9·0, –11·4 to –6·6, p<0·0001; 9 months –9·2, –11·7 to –6·8, p<0·0001; 12 months –8·9, –11·5 to –6·3, p<0·0001). Patients with frailty had significantly worse physical and role functioning
背景:患有癌症的老年人非常重视与健康相关的生活质量(HRQoL)。老年医学 8 项筛查工具可识别虚弱的个体,但其与 HRQoL 的关系仍鲜有研究。在此,我们将评估老年医学 8 筛选工具是否与老年癌症患者的短期和长期 HRQoL 相关:在这项丹麦单中心前瞻性队列研究中,对 70 岁及以上的实体瘤患者进行了老年 8 项筛查。患者在基线、3个月、6个月、9个月和12个月时填写欧洲癌症研究和治疗组织(EORTC)生活质量核心30(QLQ-C30)和老年人14(ELD14)问卷。患者特征来自医疗记录。在 12 个月内,体弱患者(定义为老年医学 8 评分≤14 分)和非体弱患者的平均总体健康状况和 QoL(GHS)差异是主要结果,GHS 采用 EORTC QLQ-C30 中关于过去一周总体健康状况和 QoL 的两个七点李克特量表问题进行测量。次要结果是平均 EORTC 总分(包括 QLQ-C30 的所有问题,但不包括 GHS 中的问题和有关经济困难的问题)和五个功能性量表(EORTC QLQ-C30 和 EORTC-QLQ-ELD14 中的身体、角色和社会功能、保持目的和家庭支持)以及五个症状量表(EORTC-QLQ-C30 和 EORTC-QLQ-ELD14 中的疲劳、疼痛、活动能力、未来担忧和疾病负担)的差异。分析采用线性混合模型进行。所有主要和次要结果都根据性别、治疗意图和癌症类型进行了调整,主要结果还通过应答者分析进行了评估:2020 年 6 月 1 日至 2021 年 10 月 15 日期间,1398 名符合条件的患者接受了老年医学 8 项筛查(其中 908 人[65%]有体弱症状,490 人[35%]无体弱症状),并提供了病历数据。在这些患者中,707 人(51%)还提供了 HRQoL 数据(437 人[62%]有体弱症状,270 人[38%]无体弱症状)。经调整后,体弱患者的 GHS 较差(-15-1,95% CI -18-5 至 -11-6;p解释:在肿瘤转诊后的 12 个月内,患有癌症且体弱的老年患者的 HRQoL 明显低于无体弱的患者。因此,通过识别和治疗虚弱,我们可以最终改善患者的 HRQoL:丹麦癌症协会、老年癌症研究学院(AgeCare)、欧登塞大学医院、南丹麦大学、达格玛-马歇尔斯基金以及阿格尼丝和普尔-弗里斯基金。
{"title":"Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study","authors":"Helena Møgelbjerg Ditzel MD ,&nbsp;Ann-Kristine Weber Giger MD PhD ,&nbsp;Cecilia Margareta Lund MD PhD ,&nbsp;Prof Henrik Jørn Ditzel MD DMSc ,&nbsp;Sören Möller PhD ,&nbsp;Prof Per Pfeiffer MD PhD ,&nbsp;Prof Jesper Ryg MD PhD ,&nbsp;Prof Marianne Ewertz MD DMSc ,&nbsp;Trine Lembrecht Jørgensen MD PhD","doi":"10.1016/S2666-7568(24)00118-1","DOIUrl":"10.1016/S2666-7568(24)00118-1","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Health-related quality of life (HRQoL) is highly valued among older adults with cancer. The Geriatric 8 screening tool identifies individuals with frailty, but its association with HRQoL remains sparsely investigated. Herein, we evaluate whether Geriatric 8 frailty is associated with short-term and long-term HRQoL in older patients with cancer.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;In this Danish single-centre, prospective cohort study, patients aged 70 years and older, referred to oncological assessment for solid cancers, were screened with the Geriatric 8. Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Core 30 (QLQ-C30) and Elderly 14 (ELD14) questionnaires at baseline, 3 months, 6 months, 9 months, and 12 months. Patient characteristics were obtained from medical records. Differences in mean global health status and QoL (GHS), measured using the two seven-point Likert scale questions from the EORTC QLQ-C30 regarding overall health and QoL during the past week, between patients with frailty (defined as a Geriatric 8 score of ≤14) and without frailty within 12 months were the primary outcome. Secondary outcomes were differences in the mean EORTC Summary Score comprised of all questions from the QLQ-C30 except for those included in the GHS and a question concerning financial difficulties, and five functional (physical, role, and social functioning, maintaining purpose, and family support from the EORTC QLQ-C30 and the EORTC-QLQ-ELD14), and five symptom scales (fatigue, pain, mobility, future worries, and burden of illness from the EORTC-QLQ-C30 and the EORTC-QLQ-ELD14). Analyses were done using linear mixed models. All primary and secondary outcomes were adjusted for gender, treatment intent, and cancer type and the primary outcome was also assessed by means of a responder analysis.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;Between June 1, 2020 and Oct 15, 2021, 1398 eligible patients were screened with the Geriatric 8 (908 [65%] with frailty and 490 [35%] without frailty) and provided medical record data. Of these patients, 707 (51%) also provided HRQoL data (437 [62%] with frailty and 270 [38%] without frailty). When adjusted, patients with frailty had poorer GHS (–15·1, 95% CI –18·5 to –11·6; p&lt;0·0001) at baseline and throughout follow-up (3 months –7·4, –11·0 to –3·7, p=0·0001; 6 months –11·7, –15·5 to –7·9, p&lt;0·0001; 9 months –10·4, –14·3 to –6·5, p&lt;0·0001; 12 months –10·4, –14·6 to –6·2, p&lt;0·0001) compared to patients without frailty. Adjusted summary scores were also poorer for patients with frailty (–9·9, 95% CI –12·1 to –7·6; p&lt;0·0001) compared to patients without frailty at baseline and throughout follow-up (3 months –8·2, –10·5 to –5·8, p=0·0001; 6 months –9·0, –11·4 to –6·6, p&lt;0·0001; 9 months –9·2, –11·7 to –6·8, p&lt;0·0001; 12 months –8·9, –11·5 to –6·3, p&lt;0·0001). Patients with frailty had significantly worse physical and role functioning","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100612"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001181/pdfft?md5=535fb239e0e39156a71823a9ffaf776a&pid=1-s2.0-S2666756824001181-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychosocial pathways linking differences in socioeconomic status to symptoms of depression 将社会经济地位差异与抑郁症状联系起来的心理社会途径。
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.07.009
Larissa Zwar
{"title":"Psychosocial pathways linking differences in socioeconomic status to symptoms of depression","authors":"Larissa Zwar","doi":"10.1016/j.lanhl.2024.07.009","DOIUrl":"10.1016/j.lanhl.2024.07.009","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100626"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001429/pdfft?md5=feca87aea0a11b8f7dc3c5c07e122d86&pid=1-s2.0-S2666756824001429-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits of population-level interventions for dementia risk factors: an economic modelling study for England 针对痴呆症风险因素的人群干预措施的益处:英格兰经济模型研究。
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/S2666-7568(24)00117-X
Prof Naaheed Mukadam PhD , Robert Anderson MA , Sebastian Walsh MPhil , Raphael Wittenberg MSc , Prof Martin Knapp PhD , Prof Carol Brayne PhD , Prof Gill Livingston MD

Background

Individual-level interventions for dementia risk factors could reduce costs associated with dementia and some are cost-effective. We aimed to estimate the cost-effectiveness of population-level interventions for tackling dementia risk factors.

Methods

In this economic modelling study, we included recommended population-based interventions from a previously published review article for which there was consistent and robust evidence of effectiveness in tackling a dementia risk factor (tobacco smoking, excess alcohol use, hypertension, obesity, air pollution, and head injury). We only included interventions if they had not been introduced in England or were in place but could be extended. The interventions studied were increases in tobacco pricing, minimum pricing for alcohol, raising alcohol price, salt reduction policies, sugar reduction policies, low emission zones, and compulsory helmet use for cycling by children (aged 5–18 years). We used published intervention effect sizes and relative risks for each risk factor and a Markov model to estimate progression to dementia in populations with and without the intervention, looking at lifetime risk, in the population of England.

Findings

We estimated that reductions in excess alcohol use through minimum unit pricing would lead to cost-savings of £280 million and 4767 quality-adjusted life-years (QALYs) gained over an indefinite succession of age cohorts. Reformulation of food products to reduce salt would lead to cost-savings of £2·4 billion and 39 433 QALYs gained and reformulation to reduce sugar would lead to cost-savings of £1·046 billion and 17 985 QALYs gained. Reducing dementia risk from air pollution by introducing low emission zones in English cities with a population of 100 000 or more (that do not already impose restrictions) would lead to £260 million cost-savings and 5119 QALYs gained. Raising cigarette prices by 10% to reduce dementia risk from smoking would lead to 2277 QALYs gained and cost-savings of £157 million. Making bicycle helmets compulsory for children (aged 5–18 years) to reduce dementia risk from head injury would lead to cost-savings of £91 million and 1554 QALYs gained.

Interpretation

Population-level interventions could help tackle life course dementia risk and save costs.

Funding

UK National Institute for Health and Care Research Three Schools dementia research programme.

背景:针对痴呆症风险因素的个人干预措施可降低痴呆症的相关成本,其中一些措施具有成本效益。我们旨在估算针对痴呆症风险因素的人群干预措施的成本效益:在这项经济模型研究中,我们纳入了之前发表的综述文章中推荐的人群干预措施,这些干预措施在应对痴呆症风险因素(吸烟、过量饮酒、高血压、肥胖、空气污染和头部损伤)方面具有一致且可靠的有效性证据。如果干预措施尚未在英格兰实施,或者已经实施但可以推广,我们才将其纳入研究范围。研究的干预措施包括提高烟草定价、酒类最低定价、提高酒类价格、减盐政策、减糖政策、低排放区以及儿童(5-18 岁)骑自行车必须戴头盔。我们使用已公布的干预效果大小和每个风险因素的相对风险,并使用马尔可夫模型来估算英格兰人口在采取干预措施和未采取干预措施的情况下痴呆症的进展情况,以终生风险为依据:我们估计,通过最低单位定价减少过量饮酒可节约成本 2.8 亿英镑,并在不确定的连续年龄组中获得 4767 个质量调整生命年(QALYs)。重新配制食品以减少盐分,可节约成本 20-4 亿英镑,获得 39 433 个质量调整生命年;重新配制食品以减少糖分,可节约成本 10-46 亿英镑,获得 17 985 个质量调整生命年。在人口达到或超过 10 万的英国城市(尚未实施限制措施)设立低排放区,降低空气污染对痴呆症造成的风险,可节约成本 2.6 亿英镑,获得 5119 QALYs。将香烟价格提高 10%,以降低吸烟导致痴呆症的风险,将带来 2277 QALYs 收益和 1.57 亿英镑的成本节约。强制规定儿童(5-18 岁)必须佩戴自行车头盔,以降低因头部受伤导致痴呆症的风险,可节约成本 9100 万英镑,获得 1554 个 QALYs:人口层面的干预措施有助于应对终生痴呆症风险并节约成本:资金来源:英国国家健康与护理研究所 "三校痴呆症研究计划"。
{"title":"Benefits of population-level interventions for dementia risk factors: an economic modelling study for England","authors":"Prof Naaheed Mukadam PhD ,&nbsp;Robert Anderson MA ,&nbsp;Sebastian Walsh MPhil ,&nbsp;Raphael Wittenberg MSc ,&nbsp;Prof Martin Knapp PhD ,&nbsp;Prof Carol Brayne PhD ,&nbsp;Prof Gill Livingston MD","doi":"10.1016/S2666-7568(24)00117-X","DOIUrl":"10.1016/S2666-7568(24)00117-X","url":null,"abstract":"<div><h3>Background</h3><p>Individual-level interventions for dementia risk factors could reduce costs associated with dementia and some are cost-effective. We aimed to estimate the cost-effectiveness of population-level interventions for tackling dementia risk factors.</p></div><div><h3>Methods</h3><p>In this economic modelling study, we included recommended population-based interventions from a previously published review article for which there was consistent and robust evidence of effectiveness in tackling a dementia risk factor (tobacco smoking, excess alcohol use, hypertension, obesity, air pollution, and head injury). We only included interventions if they had not been introduced in England or were in place but could be extended. The interventions studied were increases in tobacco pricing, minimum pricing for alcohol, raising alcohol price, salt reduction policies, sugar reduction policies, low emission zones, and compulsory helmet use for cycling by children (aged 5–18 years). We used published intervention effect sizes and relative risks for each risk factor and a Markov model to estimate progression to dementia in populations with and without the intervention, looking at lifetime risk, in the population of England.</p></div><div><h3>Findings</h3><p>We estimated that reductions in excess alcohol use through minimum unit pricing would lead to cost-savings of £280 million and 4767 quality-adjusted life-years (QALYs) gained over an indefinite succession of age cohorts. Reformulation of food products to reduce salt would lead to cost-savings of £2·4 billion and 39 433 QALYs gained and reformulation to reduce sugar would lead to cost-savings of £1·046 billion and 17 985 QALYs gained. Reducing dementia risk from air pollution by introducing low emission zones in English cities with a population of 100 000 or more (that do not already impose restrictions) would lead to £260 million cost-savings and 5119 QALYs gained. Raising cigarette prices by 10% to reduce dementia risk from smoking would lead to 2277 QALYs gained and cost-savings of £157 million. Making bicycle helmets compulsory for children (aged 5–18 years) to reduce dementia risk from head injury would lead to cost-savings of £91 million and 1554 QALYs gained.</p></div><div><h3>Interpretation</h3><p>Population-level interventions could help tackle life course dementia risk and save costs.</p></div><div><h3>Funding</h3><p>UK National Institute for Health and Care Research Three Schools dementia research programme.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100611"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266675682400117X/pdfft?md5=11cf8662075dd2811b0c703f0114287f&pid=1-s2.0-S266675682400117X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of an exercise intervention or combined exercise and diet intervention on health-related quality of life-physical functioning after kidney transplantation: the Active Care after Transplantation (ACT) multicentre randomised controlled trial 运动干预或运动与饮食相结合的干预对肾移植后与健康相关的生活质量--身体机能的影响:移植后积极护理(ACT)多中心随机对照试验
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.07.005
Tim J Knobbe MD , Daan Kremer MD , Dorien M Zelle MD PhD , Gerald Klaassen MSc , Desie Dijkema MSc , Iris M Y van Vliet PhD , Paul B Leurs MD PhD , Prof Frederike J Bemelman , Prof Maarten H L Christiaans , Prof Stefan P Berger MD PhD , Prof Gerjan Navis MD PhD , Prof Stephan J L Bakker MD PhD , Eva Corpeleijn PhD

Background

Robust evidence for interventions to improve health-related quality of life (HRQoL) in people who receive a kidney transplant is scarce. We aimed to assess the effects of a lifestyle intervention in this context.

Methods

We conducted a multicentre, open-label, parallel-group, randomised controlled trial among people who have received a kidney transplant. Participants from six hospitals across the Netherlands were randomly assigned 1:1:1 by an independent company into: usual care, exercise, and exercise plus diet. The exercise intervention encompassed two phases, a 3-month supervised exercise programme (twice weekly) followed by 12 months of lifestyle coaching, with 15 months of additional dietary counselling (12 sessions) for the exercise plus diet group. The primary outcome was HRQoL-domain physical functioning, assessed using the 36-item Short Form Survey at 15 months.

Findings

From Oct 12, 2010 to Nov 18, 2016, 221 participants who had received a kidney transplant (138 [62%] male and 83 [38%] female, with a mean age of 52·5 [SD 13·5] years, who were a median of 5·5 [IQR 3·6–8·4] months post-transplant) were included and randomly assigned to usual care (n=74), exercise intervention (n=77), and exercise plus diet intervention (n=70). In the intention-to-treat analyses, at 15 months post-baseline, no significant differences in HRQoL-domain physical functioning were found for the exercise group (5·3 arbitrary units, 95% CI –4·2 to 14·9; p=0·27), and the exercise plus diet group (5·9 arbitrary units, –4·1 to 16·0; p=0·25) compared with control. Safety outcomes showed no safety concerns. After 3 months of supervised exercise intervention, HRQoL-domain physical functioning improved in the exercise group (7·3 arbitrary units, 95% CI 1·2 to 13·3; p=0·018) but not in the exercise plus diet group (5·8 arbitrary units, –0·5 to 12·1; p=0·072).

Interpretation

A lifestyle intervention is safe and feasible in people who have received kidney transplants, paving the way for lifestyle intervention studies in other multimorbid populations with polypharmacy. However, improving HRQoL for people who have received a kidney transplant is challenging. The lifestyle interventions in the current study did not show significant improvements in HRQoL at the end of the study at the total group level.

Funding

Dutch Kidney Foundation, Innovation Fund of the Dutch Medical Insurance Companies, and University Medical Center Groningen.

背景很少有证据表明可以通过干预措施改善肾移植患者与健康相关的生活质量(HRQoL)。我们的目标是评估生活方式干预在这种情况下的效果。方法我们在肾移植患者中开展了一项多中心、开放标签、平行组、随机对照试验。来自荷兰六家医院的参与者由一家独立公司按 1:1:1 的比例随机分配到:常规护理、运动和运动加饮食。运动干预包括两个阶段,即为期 3 个月的监督运动计划(每周两次)和为期 12 个月的生活方式指导,运动加饮食组还包括为期 15 个月的额外饮食指导(12 次)。主要研究结果是15个月时使用36项简表调查对HRQoL领域的身体功能进行评估。研究结果从2010年10月12日到2016年11月18日,221名接受过肾移植的参与者(其中男性138人[62%],女性83人[38%],平均年龄52-5岁[SD 13-5岁],中位数为移植后5-5个月[IQR 3-6-8-4个月])被纳入并随机分配到常规护理组(n=74)、运动干预组(n=77)和运动加饮食干预组(n=70)。在基线后15个月的意向治疗分析中,运动组(5-3个任意单位,95% CI -4-2至14-9;P=0-27)和运动加饮食组(5-9个任意单位,-4-1至16-0;P=0-25)的HRQoL域身体功能与对照组相比无显著差异。安全结果显示没有安全问题。经过3个月的督导运动干预后,运动组的HRQoL领域身体功能有所改善(7-3个任意单位,95% CI 1-2至13-3;P=0-018),但运动加饮食组没有改善(5-8个任意单位,-0-5至12-1;P=0-072)。然而,改善肾移植患者的 HRQoL 具有挑战性。本研究中的生活方式干预措施在研究结束时并未显示出对整个群体的 HRQoL 有明显改善。
{"title":"Effect of an exercise intervention or combined exercise and diet intervention on health-related quality of life-physical functioning after kidney transplantation: the Active Care after Transplantation (ACT) multicentre randomised controlled trial","authors":"Tim J Knobbe MD ,&nbsp;Daan Kremer MD ,&nbsp;Dorien M Zelle MD PhD ,&nbsp;Gerald Klaassen MSc ,&nbsp;Desie Dijkema MSc ,&nbsp;Iris M Y van Vliet PhD ,&nbsp;Paul B Leurs MD PhD ,&nbsp;Prof Frederike J Bemelman ,&nbsp;Prof Maarten H L Christiaans ,&nbsp;Prof Stefan P Berger MD PhD ,&nbsp;Prof Gerjan Navis MD PhD ,&nbsp;Prof Stephan J L Bakker MD PhD ,&nbsp;Eva Corpeleijn PhD","doi":"10.1016/j.lanhl.2024.07.005","DOIUrl":"10.1016/j.lanhl.2024.07.005","url":null,"abstract":"<div><h3>Background</h3><p>Robust evidence for interventions to improve health-related quality of life (HRQoL) in people who receive a kidney transplant is scarce. We aimed to assess the effects of a lifestyle intervention in this context.</p></div><div><h3>Methods</h3><p>We conducted a multicentre, open-label, parallel-group, randomised controlled trial among people who have received a kidney transplant. Participants from six hospitals across the Netherlands were randomly assigned 1:1:1 by an independent company into: usual care, exercise, and exercise plus diet. The exercise intervention encompassed two phases, a 3-month supervised exercise programme (twice weekly) followed by 12 months of lifestyle coaching, with 15 months of additional dietary counselling (12 sessions) for the exercise plus diet group. The primary outcome was HRQoL-domain physical functioning, assessed using the 36-item Short Form Survey at 15 months.</p></div><div><h3>Findings</h3><p>From Oct 12, 2010 to Nov 18, 2016, 221 participants who had received a kidney transplant (138 [62%] male and 83 [38%] female, with a mean age of 52·5 [SD 13·5] years, who were a median of 5·5 [IQR 3·6–8·4] months post-transplant) were included and randomly assigned to usual care (n=74), exercise intervention (n=77), and exercise plus diet intervention (n=70). In the intention-to-treat analyses, at 15 months post-baseline, no significant differences in HRQoL-domain physical functioning were found for the exercise group (5·3 arbitrary units, 95% CI –4·2 to 14·9; p=0·27), and the exercise plus diet group (5·9 arbitrary units, –4·1 to 16·0; p=0·25) compared with control. Safety outcomes showed no safety concerns. After 3 months of supervised exercise intervention, HRQoL-domain physical functioning improved in the exercise group (7·3 arbitrary units, 95% CI 1·2 to 13·3; p=0·018) but not in the exercise plus diet group (5·8 arbitrary units, –0·5 to 12·1; p=0·072).</p></div><div><h3>Interpretation</h3><p>A lifestyle intervention is safe and feasible in people who have received kidney transplants, paving the way for lifestyle intervention studies in other multimorbid populations with polypharmacy. However, improving HRQoL for people who have received a kidney transplant is challenging. The lifestyle interventions in the current study did not show significant improvements in HRQoL at the end of the study at the total group level.</p></div><div><h3>Funding</h3><p>Dutch Kidney Foundation, Innovation Fund of the Dutch Medical Insurance Companies, and University Medical Center Groningen.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100622"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001387/pdfft?md5=458089fe15d2e09b2eea98693510e45f&pid=1-s2.0-S2666756824001387-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reserve and resilience: the cumulative risk of surgery on cognition and neurodegeneration in older individuals 储备与恢复力:手术对老年人认知和神经变性的累积风险。
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.08.003
Tammy T Hshieh
{"title":"Reserve and resilience: the cumulative risk of surgery on cognition and neurodegeneration in older individuals","authors":"Tammy T Hshieh","doi":"10.1016/j.lanhl.2024.08.003","DOIUrl":"10.1016/j.lanhl.2024.08.003","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100634"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001600/pdfft?md5=df4ef66c7ed43cea96a9eb3bdd33238d&pid=1-s2.0-S2666756824001600-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life-course financial mobility shapes later-life memory function 生命历程中的财务流动塑造了晚年的记忆功能。
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.07.011
Xiaolin Xu , Mika Kivimäki
{"title":"Life-course financial mobility shapes later-life memory function","authors":"Xiaolin Xu ,&nbsp;Mika Kivimäki","doi":"10.1016/j.lanhl.2024.07.011","DOIUrl":"10.1016/j.lanhl.2024.07.011","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100628"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001442/pdfft?md5=ca8acc97c1fb119304778c034b0eb9fe&pid=1-s2.0-S2666756824001442-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug? SGLT2 抑制剂和 GLP-1 受体激动剂:哪种是最佳抗疲劳药物?
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.lanhl.2024.08.001
Pasquale Mone , Michele Ciccarelli , Stanislovas S Jankauskas , Germano Guerra , Carmine Vecchione , Valeria Visco , Gaetano Santulli
{"title":"SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?","authors":"Pasquale Mone ,&nbsp;Michele Ciccarelli ,&nbsp;Stanislovas S Jankauskas ,&nbsp;Germano Guerra ,&nbsp;Carmine Vecchione ,&nbsp;Valeria Visco ,&nbsp;Gaetano Santulli","doi":"10.1016/j.lanhl.2024.08.001","DOIUrl":"10.1016/j.lanhl.2024.08.001","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100632"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001582/pdfft?md5=a738d8d237a2880177d0a896f7b64a1c&pid=1-s2.0-S2666756824001582-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life course financial mobility and later-life memory function and decline by gender, and race and ethnicity: an intersectional analysis of the US KHANDLE and STAR cohort studies 按性别、种族和民族划分的生命过程财务流动性与晚年记忆功能和衰退:对美国 KHANDLE 和 STAR 队列研究的交叉分析。
IF 13.4 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2024-09-01 DOI: 10.1016/S2666-7568(24)00129-6
Lindsay C Kobayashi PhD , Rachel L Peterson PhD , Xuexin Yu PhD , Justina Avila-Rieger PhD , Priscilla A Amofa-Ho MS , Clara Vila-Castelar PhD , Erika Meza PhD , C Elizabeth Shaaban PhD , Prof Rachel A Whitmer PhD , Paola Gilsanz PhD , Elizabeth Rose Mayeda

Background

Intersectionality has rarely been considered in research studies of cognitive ageing. We investigated whether life-course financial mobility is differentially associated with later-life memory function and decline across intersectional identities defined by gender, and race and ethnicity.

Methods

Data were from two harmonised multiethnic cohorts (the Kaiser Healthy Aging and Diverse Life Experiences cohort and the Study of Healthy Aging in African Americans cohort) in northern California, USA (n=2340). Life-course financial mobility, measured using a combination of self-reported financial capital measures in childhood (from birth to age 16 years) and later adulthood (at the cohort baseline) was defined as consistently high, upwardly mobile, downwardly mobile, or consistently low. We clustered individuals into 32 strata representing intersectional identities defined by life-course financial mobility combined with gender, and race and ethnicity. Verbal episodic memory was assessed using the Spanish and English Neuropsychological Assessment Scales over four waves from 2017 to 2023. Adjusted mixed-effects linear regression models were estimated with and without fixed effects of gender, race and ethnicity, and financial mobility, to evaluate whether the random effects of the intersectional identity strata contributed variance to memory beyond individual fixed effects.

Findings

Mean age was 73·6 years (SD 8·1). Of 2340 individuals, 1460 (62·4%) were women, 880 (37·6%) were men, 388 (16·6%) were Asian, 1136 (48·5%) were Black, 334 (14·3%) were Latinx, and 482 (20·6%) were White. Consistently low and downwardly mobile financial capital were strongly negatively associated with later-life memory at baseline (–0·162 SD units [95% CI –0·273 to –0·051] for consistently low and –0·171 [–0·250 to –0·092] for downwardly mobile), but not rate of change over time. Intersectional identities contributed 0·2% of memory variance after accounting for the fixed effects of gender, race and ethnicity, and financial mobility.

Interpretation

Consistently low and downward life-course financial mobility are associated with lower later-life memory function. Intersectional identities defined by financial mobility in addition to gender, and race and ethnicity, contribute negligible additional variance to later-life memory in this study setting.

Funding

US National Institute on Aging, US National Institutes of Health.

背景:认知老龄化研究很少考虑交叉性。我们研究了不同性别、种族和民族的交叉性身份,其生命历程中的财务流动性是否与晚年记忆功能和衰退有不同程度的关联:数据来自美国加利福尼亚州北部两个统一的多种族队列(凯撒健康老龄化和多样化生活经历队列和非裔美国人健康老龄化研究队列)(n=2340)。生活过程中的财务流动性采用童年(从出生到 16 岁)和成年后(在队列基线)自我报告的财务资本测量组合来衡量,被定义为持续高流动性、向上流动性、向下流动性或持续低流动性。我们将个体划分为 32 个阶层,这些阶层代表了由生命历程中的财务流动性、性别、种族和民族所定义的交叉身份。在 2017 年至 2023 年的四次波次中,我们使用西班牙语和英语神经心理评估量表对口头外显记忆进行了评估。对调整后的混合效应线性回归模型进行了估算,其中包括和不包括性别、种族和民族以及经济流动性的固定效应,以评估交叉身份分层的随机效应是否超越了个人固定效应而对记忆力产生影响:平均年龄为 73-6 岁(SD 8-1)。在 2340 人中,女性 1460 人(62-4%),男性 880 人(37-6%),亚裔 388 人(16-6%),黑人 1136 人(48-5%),拉丁裔 334 人(14-3%),白人 482 人(20-6%)。金融资本持续偏低和向下流动与基线时的晚年记忆密切负相关(持续偏低为-0-162 SD单位[95% CI -0-273至-0-051],向下流动为-0-171[-0-250至-0-092]),但与随时间变化的比率无关。在考虑了性别、种族和民族以及经济流动性的固定效应后,交叉身份占记忆方差的 0-2%:解释:生命过程中持续较低的财务流动性和下降的财务流动性与较低的晚年记忆功能有关。在这项研究中,除了性别、种族和民族之外,由财务流动性定义的交叉身份对晚年记忆造成的额外差异微乎其微:美国国家老龄化研究所、美国国立卫生研究院。
{"title":"Life course financial mobility and later-life memory function and decline by gender, and race and ethnicity: an intersectional analysis of the US KHANDLE and STAR cohort studies","authors":"Lindsay C Kobayashi PhD ,&nbsp;Rachel L Peterson PhD ,&nbsp;Xuexin Yu PhD ,&nbsp;Justina Avila-Rieger PhD ,&nbsp;Priscilla A Amofa-Ho MS ,&nbsp;Clara Vila-Castelar PhD ,&nbsp;Erika Meza PhD ,&nbsp;C Elizabeth Shaaban PhD ,&nbsp;Prof Rachel A Whitmer PhD ,&nbsp;Paola Gilsanz PhD ,&nbsp;Elizabeth Rose Mayeda","doi":"10.1016/S2666-7568(24)00129-6","DOIUrl":"10.1016/S2666-7568(24)00129-6","url":null,"abstract":"<div><h3>Background</h3><p>Intersectionality has rarely been considered in research studies of cognitive ageing. We investigated whether life-course financial mobility is differentially associated with later-life memory function and decline across intersectional identities defined by gender, and race and ethnicity.</p></div><div><h3>Methods</h3><p>Data were from two harmonised multiethnic cohorts (the Kaiser Healthy Aging and Diverse Life Experiences cohort and the Study of Healthy Aging in African Americans cohort) in northern California, USA (n=2340). Life-course financial mobility, measured using a combination of self-reported financial capital measures in childhood (from birth to age 16 years) and later adulthood (at the cohort baseline) was defined as consistently high, upwardly mobile, downwardly mobile, or consistently low. We clustered individuals into 32 strata representing intersectional identities defined by life-course financial mobility combined with gender, and race and ethnicity. Verbal episodic memory was assessed using the Spanish and English Neuropsychological Assessment Scales over four waves from 2017 to 2023. Adjusted mixed-effects linear regression models were estimated with and without fixed effects of gender, race and ethnicity, and financial mobility, to evaluate whether the random effects of the intersectional identity strata contributed variance to memory beyond individual fixed effects.</p></div><div><h3>Findings</h3><p>Mean age was 73·6 years (SD 8·1). Of 2340 individuals, 1460 (62·4%) were women, 880 (37·6%) were men, 388 (16·6%) were Asian, 1136 (48·5%) were Black, 334 (14·3%) were Latinx, and 482 (20·6%) were White. Consistently low and downwardly mobile financial capital were strongly negatively associated with later-life memory at baseline (–0·162 SD units [95% CI –0·273 to –0·051] for consistently low and –0·171 [–0·250 to –0·092] for downwardly mobile), but not rate of change over time. Intersectional identities contributed 0·2% of memory variance after accounting for the fixed effects of gender, race and ethnicity, and financial mobility.</p></div><div><h3>Interpretation</h3><p>Consistently low and downward life-course financial mobility are associated with lower later-life memory function. Intersectional identities defined by financial mobility in addition to gender, and race and ethnicity, contribute negligible additional variance to later-life memory in this study setting.</p></div><div><h3>Funding</h3><p>US National Institute on Aging, US National Institutes of Health.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"5 9","pages":"Article 100613"},"PeriodicalIF":13.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824001296/pdfft?md5=e05617b92e985c04bf8be870390e4a3d&pid=1-s2.0-S2666756824001296-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Healthy Longevity
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1